583 related articles for article (PubMed ID: 32070346)
21. Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.
Yurista SR; Silljé HHW; van Goor H; Hillebrands JL; Heerspink HJL; de Menezes Montenegro L; Oberdorf-Maass SU; de Boer RA; Westenbrink BD
Cardiovasc Drugs Ther; 2020 Jun; 34(3):311-321. PubMed ID: 32185580
[TBL] [Abstract][Full Text] [Related]
22. Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome.
van Dijk CG; Oosterhuis NR; Xu YJ; Brandt M; Paulus WJ; van Heerebeek L; Duncker DJ; Verhaar MC; Fontoura D; Lourenço AP; Leite-Moreira AF; Falcão-Pires I; Joles JA; Cheng C
Circ Heart Fail; 2016 Apr; 9(4):e002760. PubMed ID: 27056881
[TBL] [Abstract][Full Text] [Related]
23. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
[TBL] [Abstract][Full Text] [Related]
24. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
[TBL] [Abstract][Full Text] [Related]
25. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
27. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
28. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Takasu T; Takakura S
Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
[TBL] [Abstract][Full Text] [Related]
29. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
[TBL] [Abstract][Full Text] [Related]
30. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.
Winzer EB; Schauer A; Langner E; Augstein A; Goto K; Männel A; Barthel P; Jannasch A; Labeit S; Mangner N; Linke A; Adams V
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232292
[TBL] [Abstract][Full Text] [Related]
32. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
33. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
34. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence.
Khemais-Benkhiat S; Belcastro E; Idris-Khodja N; Park SH; Amoura L; Abbas M; Auger C; Kessler L; Mayoux E; Toti F; Schini-Kerth VB
J Cell Mol Med; 2020 Feb; 24(3):2109-2122. PubMed ID: 30929316
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
Jhuo SJ; Liu IH; Tasi WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34198942
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat.
Manne NDPK; Ginjupalli GK; Rice KM; Arvapalli R; Graffeo VA; Bandarupalli VVK; Blough ER
Exp Clin Endocrinol Diabetes; 2020 Aug; 128(8):512-519. PubMed ID: 30616241
[TBL] [Abstract][Full Text] [Related]
38. Preventive Beneficial Effect of an Aqueous Extract of Phyllanthus amarus Schum. and Thonn. (Euphorbiaceae) on DOCA-Salt-Induced Hypertension, Cardiac Hypertrophy and Dysfunction, and Endothelial Dysfunction in Rats.
Yao NA; Niazi ZR; Najmanová I; Kamagaté M; Said A; Chabert P; Auger C; Die-Kakou H; Schini-Kerth V
J Cardiovasc Pharmacol; 2020 Jun; 75(6):573-583. PubMed ID: 32187164
[TBL] [Abstract][Full Text] [Related]
39. Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction.
Leite S; Cerqueira RJ; Ibarrola J; Fontoura D; Fernández-Celis A; Zannad F; Falcão-Pires I; Paulus WJ; Leite-Moreira AF; Rossignol P; López-Andrés N; Lourenço AP
Circ Heart Fail; 2019 Jul; 12(7):e005596. PubMed ID: 31525070
[TBL] [Abstract][Full Text] [Related]
40. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
